We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Regulatory News (EDEN)

Share Price Information for Eden (EDEN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.25
Bid: 4.20
Ask: 4.30
Change: 0.175 (4.29%)
Spread: 0.10 (2.381%)
Open: 4.075
High: 4.25
Low: 4.075
Prev. Close: 4.075
EDEN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Approval of Cedroz in Mexico

19 Dec 2019 07:00

RNS Number : 3968X
Eden Research plc
19 December 2019
 

19 December 2019

 

 

 

 

Eden Research plc

 

("Eden" or "Company")

Approval of Cedroz in Mexico and access to the US agricultural import market

Eden Research plc (AIM: EDEN), the AIM listed company that develops and supplies breakthrough biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries, is pleased to announce that its commercial partner, Eastman Chemical Company ("Eastman"), has received full authorisation for Eden's nematicide formulation, marketed as Cedroz™ by Eastman, in Mexico.

Key highlights of the authorisation:

·; Access now gained into the all-important US agricultural import market

·; Approval is the first for Eden developed products in Mexico and a foothold into the Americas

·; US imports of agricultural products from Mexico totalled $26bn in 2018

·; Cedroz is formulated with Eden's Sustaineä encapsulation and delivery technology for its improved bioactivity, controlling volatility and advanced crop safety

Cedroz is an innovative and natural solution designed to fight nematodes, a pest that is known to cause severe damage to crops globally, in both open field and greenhouse production resulting in yield losses and increasing farmers' costs. Mexico has authorised the use of Cedroz on a wide range of crops, including tomatoes, potatoes, peppers, eggplants, melons, chili peppers, pepinos and squash.

The approval in Mexico represents the first for Cedroz, or any Eden-developed product, in the Americas. U.S. imports of agricultural products from Mexico totalled $26 billion in 2018, with Mexico being the largest supplier of agricultural products to the U.S. According to the U.S. Trade Representative, the leading categories of agricultural products from Mexico in 2018 included fresh vegetables ($5.9 billion), with the leading crops including tomatoes and peppers, along with other fresh fruit ($5.8 billion). Processed fruit and vegetables accounted for another $1.7 billion.

As Mexico is a large exporter of fresh produce to the U.S., this is a commercially important territory for Eastman who registered and will distribute Cedroz supplied by Eden.

Cedroz offers growers tremendous advantages by providing high levels of efficacy against nematodes. The active ingredients in Cedroz are exempt from residue limits and have very low or no pre-harvest intervals, giving growers the ability to apply the product just prior to harvest, providing maximum benefits and flexibility.

Cedroz is formulated with Eden's Sustaineä encapsulation and delivery technology, a proven system derived from yeast. Sustaine microcapsules are naturally sourced, plastic-free, biodegradable micro-spheres derived from yeast. The Sustaine technology has enabled the safe and effective use of Eden's registered active ingredients and those of third parties by improving bioactivity, controlling volatility and improving crop safety.

Sean Smith, Chief Executive Officer of Eden, said: "We are very pleased that Eastman has received authorisation for Cedroz as this will ultimately allow Eden developed products to enter into the Americas for the first time, where demand for more natural, biopesticide solutions is rapidly increasing. The market opportunity in Mexico is significant for Eden and Eastman thanks to the demand for residue-free fruit and vegetables by U.S. consumers.

Eastman will now embark on a roll-out of Cedroz in the coming year, which includes extensive live trials under local conditions to determine the best possible use of Cedroz in different scenarios and for a range of crops. Experience has shown that an extensive and controlled trial period is essential to the success of such a product launch."

 

For further information contact:

Eden Research plc

www.edenresearch.com

Sean Smith

Alex Abrey

01285 359 555

 

Cenkos Securities (Nominated advisor and broker)

Giles Balleny / Cameron MacRitchie (corporate finance)Michael Johnson (sales)

020 7397 8900

 

Powerscourt (Financial PR)

Nick Dibden

Courtney Sanford

 

020 7250 1446

eden@powerscourt-group.com

 

 

Notes:

 

Eden Research is an AIM listed company that develops and supplies breakthrough biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries

 

Eden's Sustaineä encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can be used with both natural and synthetic compounds to enhance their performance and ease-of-use.

 

Sustaine microcapsules are naturally derived, plastic-free, biodegradable micro-spheres derived from yeast extract. They produce stabilised aqueous suspensions which, are easy to mix and apply, have phased release patterns, are safer for the environment and the crops themselves.

 

The European Chemicals Agency (ECHA) has proposed an EU-wide restriction on the placing on the market or use of "intentionally-added" microplastic particles. The proposed restriction includes the use of microplastics for agricultural and horticultural purposes, including polymers utilized for controlled-release fertilizers, encapsulated plant protection products (PPPs), seed coatings, and biocides.

 

By 2025 in the EU, pesticides containing synthetic polymer microplastics are likely to be banned and removed from the market. The only acceptable alternative is the substitution with biodegradable formulations. Reformulated products will need to be evaluated and registered within the five-year transition period.

 

Sustaine is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

 

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Sustaine provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

 

Eden is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

 

The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £14m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements. 

 

In May 2013, the three actives that comprise Eden's first commercial product, Mevalone, were approved as new ingredients for use in plant protection products by the European Commission ("EC"). This represented a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company. To illustrate this point, one should note that in 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.

 

Mevaloneä is a foliar fungicide which has been authorised for sale in Kenya, Malta, Greece, Bulgaria,

Spain, Italy, France, Cyprus, Albania, Portugal and Macedonia.

 

Cedrozä is a nematicide which has been authorised for sale in Malta, Belgium and Mexico.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

 

For more information about Eden, please visit: www.edenresearch.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

 

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCDVLFFKLFZFBQ
Date   Source Headline
19th Jun 20187:00 amRNSDirector/PDMR Shareholding
14th Jun 20187:00 amRNSRegulatory Progress Update
30th May 20182:30 pmRNSPosting of Annual Report & Notice of AGM
10th May 20185:04 pmRNSDirector/PDMR Shareholding
8th May 20187:00 amRNSExercise of Options
20th Mar 20187:00 amRNSPreliminary results
11th Jan 20187:00 amRNSYear-end Trading Statement
12th Dec 20177:00 amRNSRegulatory Progress Update
29th Sep 201711:15 amRNSHalf-year Report - Replacement
29th Sep 20177:30 amRNSAdoption of New LTIP and Grant of Awards
29th Sep 20177:01 amRNSBoard Changes
29th Sep 20177:00 amRNSHalf-year Report
25th Sep 20177:00 amRNSApproval of MevaloneT in Portugal
1st Sep 20177:00 amRNSNotice of Results
30th Jun 20175:14 pmRNSHolding(s) in Company
30th Jun 201712:29 pmRNSResult of AGM
30th Jun 20177:43 amRNSAGM Statement
30th Jun 20177:39 amRNSCompletion of Placing & Subscription
30th Jun 20177:00 amRNSSipcam agreements, investment and proposed placing
29th Jun 20179:43 amRNSNew terms agreed with UMMS
5th Jun 20173:14 pmRNSPosting of Annual Report & Notice of AGM
22nd May 20177:00 amRNSFinal Results
11th May 20179:00 amRNSEden Research on BBC Radio 4's You & Yours
29th Mar 20177:00 amRNSExtension of patent protection in Greece
8th Mar 20172:40 pmRNSVoting Rights, Warrants and Options Outstanding
23rd Jan 20172:00 pmRNSPrice Monitoring Extension
23rd Jan 20177:00 amRNSFungicide product approved for sale in France
21st Dec 20167:01 amRNSTrading update
21st Dec 20167:00 amRNSEastman commercialisation agreement for nematicide
27th Sep 20167:00 amRNSHalf-year Report
28th Jun 201612:28 pmRNSResult of AGM
28th Jun 20167:00 amRNSAGM Statement
15th Jun 20167:00 amRNSLabel extensions for 3AEY in Spain and Greece
7th Jun 20167:00 amRNSPosting of Annual Report & Notice of AGM
26th May 20163:36 pmRNSDirector/PDMR Shareholding
24th May 20167:00 amRNSFinal Results
11th Apr 20169:31 amRNSHolding(s) in Company
30th Mar 20167:00 amRNSPlacing to raise £2.6m
22nd Feb 20167:00 amRNSApproval of 3AEY in Spain
11th Feb 20167:00 amRNSApproval of 3AEY in Italy
10th Feb 20167:00 amRNSFirst shipment of MevaloneT (3AEY) to Greece
21st Jan 20167:00 amRNSExercise of options
14th Jan 20167:00 amRNSFurther progress with EU product approvals
16th Nov 20157:00 amRNSKenya approval & first commercial-scale order
26th Oct 20157:00 amRNSAppointment of Nominated Adviser and Broker
24th Sep 20157:00 amRNSCollaboration and Licence Agreement Signed
15th Sep 20157:00 amRNSHalf Yearly Report
1st Sep 20157:03 amRNSProduct approval in Greece
24th Aug 20157:00 amRNSTerpeneTech Licence Agreement and Investment
25th Jun 20157:00 amRNSActive substances approved for MRL exemption

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.